{"id":67668,"date":"2026-06-08T15:11:14","date_gmt":"2026-06-08T07:11:14","guid":{"rendered":"https:\/\/flcube.com\/?p=67668"},"modified":"2026-06-08T15:11:15","modified_gmt":"2026-06-08T07:11:15","slug":"bayers-kerendia-finerenone-demonstrates-significant-kidney-protection-in-non-diabetic-ckd-phase-iii-trial-first-mineralocorticoid-receptor-antagonist-to-show-efficacy-beyond-diabetes-pop","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67668","title":{"rendered":"Bayer&#8217;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bayer AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BAYN:ETR\">ETR: BAYN<\/a>) announced positive results from a pivotal <strong>Phase III study<\/strong> presented at the <strong>63rd European Renal Association (ERA) Congress<\/strong>, demonstrating that <strong>Kerendia (finerenone)<\/strong> significantly reduced kidney disease progression in adults with <strong>non-diabetic chronic kidney disease (nd-CKD)<\/strong>. The trial met its primary endpoint with a statistically significant improvement in <strong>estimated glomerular filtration rate (eGFR) slope<\/strong>, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia&#8217;s addressable market beyond its current diabetic CKD indication.<\/p>\n\n\n\n<h2 id=\"h-primary-endpoint-kidney-function-preservation\" class=\"wp-block-heading\">Primary Endpoint: Kidney Function Preservation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Kerendia<\/th><th>Placebo<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>eGFR slope (mean annual change)<\/td><td>eGFR slope (mean annual change)<\/td><td><strong>Statistically significant reduction in kidney disease progression<\/strong><\/td><\/tr><tr><td><strong>Measurement Period<\/strong><\/td><td>Baseline to month 32<\/td><td>Baseline to month 32<\/td><td>Clinically meaningful preservation of kidney function<\/td><\/tr><tr><td><strong>Background Therapy<\/strong><\/td><td>Standard of care for nd-CKD<\/td><td>Standard of care for nd-CKD<\/td><td>Added benefit on top of current standard treatments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-secondary-composite-kidney-cardiovascular-endpoint\" class=\"wp-block-heading\">Secondary Composite Kidney-Cardiovascular Endpoint<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Components:<\/strong> Kidney failure, sustained eGFR decline \u226557%, hospitalization for heart failure, or cardiovascular death<\/li>\n\n\n\n<li><strong>Result:<\/strong> <strong>Statistically significant risk reduction<\/strong> vs. placebo<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong> First mineralocorticoid receptor antagonist to demonstrate dual kidney-cardiovascular protection in non-diabetic population<\/li>\n\n\n\n<li><strong>Market Significance:<\/strong> Addresses critical unmet need in 60% of CKD patients who do not have diabetes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-safety-profile-amp-tolerability\" class=\"wp-block-heading\">Safety Profile &amp; Tolerability<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Adverse Event Type<\/th><th>Kerendia Group<\/th><th>Placebo Group<\/th><th>Clinical Assessment<\/th><\/tr><\/thead><tbody><tr><td><strong>Treatment-Emergent AEs (TEAEs)<\/strong><\/td><td>68.3%<\/td><td>65.4%<\/td><td>Comparable overall safety<\/td><\/tr><tr><td><strong>Treatment-Emergent Serious AEs (TESAEs)<\/strong><\/td><td>20.9%<\/td><td>21.2%<\/td><td>No increased serious event risk<\/td><\/tr><tr><td><strong>Hyperkalemia (AESI)<\/strong><\/td><td>17.0%<\/td><td>13.3%<\/td><td>Expected class effect, manageable<\/td><\/tr><tr><td><strong>Severe Hyperkalemia<\/strong><\/td><td>&lt;1%<\/td><td>Not specified<\/td><td>Low clinical significance<\/td><\/tr><tr><td><strong>Hyperkalemia Leading to Discontinuation<\/strong><\/td><td>&lt;2%<\/td><td>Not specified<\/td><td>Minimal impact on treatment adherence<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-opportunity-amp-commercial-implications\" class=\"wp-block-heading\">Market Opportunity &amp; Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> 450 million people globally with CKD; 60% (270 million) have non-diabetic etiology<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> No approved therapies specifically indicated for nd-CKD progression<\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> First and only mineralocorticoid receptor antagonist with proven efficacy in both diabetic and non-diabetic CKD<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Could double Kerendia&#8217;s current $1.2B annual sales with nd-CKD approval<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Supplemental NDA\/MAA submission expected Q3 2026 with potential approval in H1 2027<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-innovation-amp-mechanism\" class=\"wp-block-heading\">Scientific Innovation &amp; Mechanism<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Selective MRA:<\/strong> Finerenone&#8217;s non-steroidal structure provides tissue-selective anti-inflammatory and anti-fibrotic effects<\/li>\n\n\n\n<li><strong>Beyond Blood Pressure:<\/strong> Kidney protection independent of blood pressure lowering effects<\/li>\n\n\n\n<li><strong>Cardio-Renal Axis:<\/strong> Simultaneously addresses both kidney and cardiovascular components of CKD progression<\/li>\n\n\n\n<li><strong>Inflammation Targeting:<\/strong> Reduces oxidative stress and inflammatory pathways driving fibrosis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-bayer\" class=\"wp-block-heading\">Strategic Significance for Bayer<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Franchise Expansion:<\/strong> Transforms Kerendia from diabetes-focused to broad CKD therapy<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Strengthens cardiovascular and renal therapeutic areas<\/li>\n\n\n\n<li><strong>Competitive Defense:<\/strong> Creates significant barrier to entry for competing MRAs<\/li>\n\n\n\n<li><strong>Pricing Power:<\/strong> Premium positioning justified by first-in-class status in nd-CKD<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-timeline-amp-next-steps\" class=\"wp-block-heading\">Development Timeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Submissions:<\/strong> Global filings planned for Q3-Q4 2026<\/li>\n\n\n\n<li><strong>Label Expansion:<\/strong> Current label limited to type 2 diabetes with albuminuric CKD<\/li>\n\n\n\n<li><strong>Real-World Evidence:<\/strong> Post-marketing studies to validate trial findings in diverse populations<\/li>\n\n\n\n<li><strong>Combination Strategies:<\/strong> Investigational protocols with SGLT2 inhibitors and RAS inhibitors<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Kerendia. Actual results may differ due to final regulatory decisions, competitive dynamics, market adoption rates, and evolving treatment guidelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at&#8230;<\/p>\n","protected":false},"author":1,"featured_media":67670,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,269,17,967],"class_list":["post-67668","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-bayer","tag-clinical-trial-results","tag-etr-bayn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bayer&#039;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia&#039;s addressable market beyond its current diabetic CKD indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67668\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer&#039;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population\" \/>\n<meta property=\"og:description\" content=\"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia&#039;s addressable market beyond its current diabetic CKD indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67668\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-08T07:11:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-08T07:11:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bayer&#8217;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population\",\"datePublished\":\"2026-06-08T07:11:14+00:00\",\"dateModified\":\"2026-06-08T07:11:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0803.webp\",\"keywords\":[\"Academic conference\",\"Bayer\",\"Clinical trial results\",\"ETR: BAYN\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67668#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67668\",\"name\":\"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0803.webp\",\"datePublished\":\"2026-06-08T07:11:14+00:00\",\"dateModified\":\"2026-06-08T07:11:15+00:00\",\"description\":\"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia's addressable market beyond its current diabetic CKD indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67668\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/0803.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67668#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer&#8217;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population - Insight, China&#039;s Pharmaceutical Industry","description":"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia's addressable market beyond its current diabetic CKD indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67668","og_locale":"en_US","og_type":"article","og_title":"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population","og_description":"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia's addressable market beyond its current diabetic CKD indication.","og_url":"https:\/\/flcube.com\/?p=67668","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-08T07:11:14+00:00","article_modified_time":"2026-06-08T07:11:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67668#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67668"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bayer&#8217;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population","datePublished":"2026-06-08T07:11:14+00:00","dateModified":"2026-06-08T07:11:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67668"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=67668#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","keywords":["Academic conference","Bayer","Clinical trial results","ETR: BAYN"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67668#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67668","url":"https:\/\/flcube.com\/?p=67668","name":"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=67668#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=67668#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","datePublished":"2026-06-08T07:11:14+00:00","dateModified":"2026-06-08T07:11:15+00:00","description":"Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at the 63rd European Renal Association (ERA) Congress, demonstrating that Kerendia (finerenone) significantly reduced kidney disease progression in adults with non-diabetic chronic kidney disease (nd-CKD). The trial met its primary endpoint with a statistically significant improvement in estimated glomerular filtration rate (eGFR) slope, while also showing robust kidney-cardiovascular protection, potentially expanding Kerendia's addressable market beyond its current diabetic CKD indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67668#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67668"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=67668#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","width":1080,"height":608,"caption":"Bayer's Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67668#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bayer&#8217;s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial \u2013 First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/0803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67668"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67668\/revisions"}],"predecessor-version":[{"id":67671,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67668\/revisions\/67671"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/67670"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}